Skip to main content

Press releases

2018-02-13
STRONG GROWTH FOR KERASAL NAIL INCREASES EBITDA
2018-02-06
STOCKHOLM, February 6th, 2018 - On February 13th 2018, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Year-end report 2017. Investors, analysts and journalists are hereby invited to participate in a teleconference at 03:00 pm (CET) on the same date.
2018-01-15
STOCKHOLM, January 15th, 2018 - Moberg Pharma AB (OMX: MOB) have received a positive outcome from the NAD (National Advertising Division) regarding a challenge filed on Fungi-Nail, the largest U.S. competitor to the Kerasal Nail® product. NAD recommends the advertiser to discontinue current product packaging and commercials. Moberg Pharma expects the outcome to further strengthen Kerasal Nails® position and growth prospects in the U.S. market.